Hyperhomocysteinaemia in treated patients with Huntington's disease homocysteine in HD.
Identifieur interne : 003544 ( PubMed/Corpus ); précédent : 003543; suivant : 003545Hyperhomocysteinaemia in treated patients with Huntington's disease homocysteine in HD.
Auteurs : Jürgen Andrich ; Carsten Saft ; Anneliese Arz ; Birgit Schneider ; Markus W. Agelink ; Peter H. Kraus ; Wilfried Kuhn ; Thomas MüllerSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2004.
English descriptors
- KwdEn :
- Adult, Biological Markers (blood), Central Nervous System Agents (administration & dosage), Central Nervous System Agents (adverse effects), Central Nervous System Agents (pharmacokinetics), Disease Progression, Drug Interactions, Female, Homocysteine (blood), Humans, Huntington Disease (blood), Huntington Disease (diagnosis), Huntington Disease (drug therapy), Hyperhomocysteinemia (blood), Hyperhomocysteinemia (diagnosis), Male, Metabolic Clearance Rate (drug effects), Middle Aged, Mutation (genetics), Nerve Tissue Proteins (genetics), Neurologic Examination, Nuclear Proteins (genetics).
- MESH :
- chemical , administration & dosage : Central Nervous System Agents.
- chemical , adverse effects : Central Nervous System Agents.
- chemical , blood : Biological Markers, Homocysteine.
- chemical , genetics : Nerve Tissue Proteins, Nuclear Proteins.
- chemical , pharmacokinetics : Central Nervous System Agents.
- blood : Huntington Disease, Hyperhomocysteinemia.
- diagnosis : Huntington Disease, Hyperhomocysteinemia.
- drug effects : Metabolic Clearance Rate.
- drug therapy : Huntington Disease.
- genetics : Mutation.
- Adult, Disease Progression, Drug Interactions, Female, Humans, Male, Middle Aged, Neurologic Examination.
Abstract
Significantly increased plasma total homocysteine levels (t-Hcys) appeared in treated Huntington disease (HD) patients compared to controls and untreated HD subjects. Because the protein Huntingtin interacts with the homocysteine metabolism modulating enzyme cystathionine beta-synthase, we hypothesize that homocysteine promotes neurodegeneration in HD.
DOI: 10.1002/mds.10629
PubMed: 14978683
Links to Exploration step
pubmed:14978683Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Hyperhomocysteinaemia in treated patients with Huntington's disease homocysteine in HD.</title><author><name sortKey="Andrich, Jurgen" sort="Andrich, Jurgen" uniqKey="Andrich J" first="Jürgen" last="Andrich">Jürgen Andrich</name><affiliation><nlm:affiliation>Department of Neurology, St. Josef Hospital, Ruhr University Bochum, Bochum, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Saft, Carsten" sort="Saft, Carsten" uniqKey="Saft C" first="Carsten" last="Saft">Carsten Saft</name></author><author><name sortKey="Arz, Anneliese" sort="Arz, Anneliese" uniqKey="Arz A" first="Anneliese" last="Arz">Anneliese Arz</name></author><author><name sortKey="Schneider, Birgit" sort="Schneider, Birgit" uniqKey="Schneider B" first="Birgit" last="Schneider">Birgit Schneider</name></author><author><name sortKey="Agelink, Markus W" sort="Agelink, Markus W" uniqKey="Agelink M" first="Markus W" last="Agelink">Markus W. Agelink</name></author><author><name sortKey="Kraus, Peter H" sort="Kraus, Peter H" uniqKey="Kraus P" first="Peter H" last="Kraus">Peter H. Kraus</name></author><author><name sortKey="Kuhn, Wilfried" sort="Kuhn, Wilfried" uniqKey="Kuhn W" first="Wilfried" last="Kuhn">Wilfried Kuhn</name></author><author><name sortKey="Muller, Thomas" sort="Muller, Thomas" uniqKey="Muller T" first="Thomas" last="Müller">Thomas Müller</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2004">2004</date><idno type="RBID">pubmed:14978683</idno><idno type="pmid">14978683</idno><idno type="doi">10.1002/mds.10629</idno><idno type="wicri:Area/PubMed/Corpus">003544</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Hyperhomocysteinaemia in treated patients with Huntington's disease homocysteine in HD.</title><author><name sortKey="Andrich, Jurgen" sort="Andrich, Jurgen" uniqKey="Andrich J" first="Jürgen" last="Andrich">Jürgen Andrich</name><affiliation><nlm:affiliation>Department of Neurology, St. Josef Hospital, Ruhr University Bochum, Bochum, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Saft, Carsten" sort="Saft, Carsten" uniqKey="Saft C" first="Carsten" last="Saft">Carsten Saft</name></author><author><name sortKey="Arz, Anneliese" sort="Arz, Anneliese" uniqKey="Arz A" first="Anneliese" last="Arz">Anneliese Arz</name></author><author><name sortKey="Schneider, Birgit" sort="Schneider, Birgit" uniqKey="Schneider B" first="Birgit" last="Schneider">Birgit Schneider</name></author><author><name sortKey="Agelink, Markus W" sort="Agelink, Markus W" uniqKey="Agelink M" first="Markus W" last="Agelink">Markus W. Agelink</name></author><author><name sortKey="Kraus, Peter H" sort="Kraus, Peter H" uniqKey="Kraus P" first="Peter H" last="Kraus">Peter H. Kraus</name></author><author><name sortKey="Kuhn, Wilfried" sort="Kuhn, Wilfried" uniqKey="Kuhn W" first="Wilfried" last="Kuhn">Wilfried Kuhn</name></author><author><name sortKey="Muller, Thomas" sort="Muller, Thomas" uniqKey="Muller T" first="Thomas" last="Müller">Thomas Müller</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2004" type="published">2004</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Biological Markers (blood)</term><term>Central Nervous System Agents (administration & dosage)</term><term>Central Nervous System Agents (adverse effects)</term><term>Central Nervous System Agents (pharmacokinetics)</term><term>Disease Progression</term><term>Drug Interactions</term><term>Female</term><term>Homocysteine (blood)</term><term>Humans</term><term>Huntington Disease (blood)</term><term>Huntington Disease (diagnosis)</term><term>Huntington Disease (drug therapy)</term><term>Hyperhomocysteinemia (blood)</term><term>Hyperhomocysteinemia (diagnosis)</term><term>Male</term><term>Metabolic Clearance Rate (drug effects)</term><term>Middle Aged</term><term>Mutation (genetics)</term><term>Nerve Tissue Proteins (genetics)</term><term>Neurologic Examination</term><term>Nuclear Proteins (genetics)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Central Nervous System Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Central Nervous System Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Biological Markers</term><term>Homocysteine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Nerve Tissue Proteins</term><term>Nuclear Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Central Nervous System Agents</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Huntington Disease</term><term>Hyperhomocysteinemia</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Huntington Disease</term><term>Hyperhomocysteinemia</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Metabolic Clearance Rate</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Huntington Disease</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Mutation</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Disease Progression</term><term>Drug Interactions</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Neurologic Examination</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Significantly increased plasma total homocysteine levels (t-Hcys) appeared in treated Huntington disease (HD) patients compared to controls and untreated HD subjects. Because the protein Huntingtin interacts with the homocysteine metabolism modulating enzyme cystathionine beta-synthase, we hypothesize that homocysteine promotes neurodegeneration in HD.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">14978683</PMID><DateCreated><Year>2004</Year><Month>02</Month><Day>23</Day></DateCreated><DateCompleted><Year>2004</Year><Month>08</Month><Day>02</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>19</Volume><Issue>2</Issue><PubDate><Year>2004</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Hyperhomocysteinaemia in treated patients with Huntington's disease homocysteine in HD.</ArticleTitle><Pagination><MedlinePgn>226-8</MedlinePgn></Pagination><Abstract><AbstractText>Significantly increased plasma total homocysteine levels (t-Hcys) appeared in treated Huntington disease (HD) patients compared to controls and untreated HD subjects. Because the protein Huntingtin interacts with the homocysteine metabolism modulating enzyme cystathionine beta-synthase, we hypothesize that homocysteine promotes neurodegeneration in HD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Andrich</LastName><ForeName>Jürgen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, St. Josef Hospital, Ruhr University Bochum, Bochum, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saft</LastName><ForeName>Carsten</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Arz</LastName><ForeName>Anneliese</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Birgit</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Agelink</LastName><ForeName>Markus W</ForeName><Initials>MW</Initials></Author><Author ValidYN="Y"><LastName>Kraus</LastName><ForeName>Peter H</ForeName><Initials>PH</Initials></Author><Author ValidYN="Y"><LastName>Kuhn</LastName><ForeName>Wilfried</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Müller</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biological Markers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002491">Central Nervous System Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C086055">HTT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009687">Nuclear Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0LVT1QZ0BA</RegistryNumber><NameOfSubstance UI="D006710">Homocysteine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015415">Biological Markers</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002491">Central Nervous System Agents</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000008">administration & dosage</QualifierName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000493">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018450">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004347">Drug Interactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006710">Homocysteine</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000097">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006816">Huntington Disease</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D020138">Hyperhomocysteinemia</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000097">blood</QualifierName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008657">Metabolic Clearance Rate</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009154">Mutation</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009419">Nerve Tissue Proteins</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009460">Neurologic Examination</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009687">Nuclear Proteins</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>2</Month><Day>24</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>8</Month><Day>3</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>2</Month><Day>24</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">14978683</ArticleId><ArticleId IdType="doi">10.1002/mds.10629</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003544 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 003544 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:14978683
|texte= Hyperhomocysteinaemia in treated patients with Huntington's disease homocysteine in HD.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:14978683" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |